ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Oncology Immuno Drug Market Research Report 2025
Published Date: July 2025
|
Report Code: QYRE-Auto-13A10237
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Oncology Immuno Drug Market Insights Forecast to 2028
BUY CHAPTERS

Global Oncology Immuno Drug Market Research Report 2025

Code: QYRE-Auto-13A10237
Report
July 2025
Pages:86
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Bristol–Myers Squibb
Merck
Roche
Astrazeneca plc
Sanofi
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc
Merck KGaA

Oncology Immuno Drug Market Size

The global market for Oncology Immuno Drug was valued at US$ 2541 million in the year 2024 and is projected to reach a revised size of US$ 4395 million by 2031, growing at a CAGR of 8.3% during the forecast period.

Oncology Immuno Drug Market

Oncology Immuno Drug Market

Immuno-Oncology (I-O) is an innovative area of research that seeks to help the body"s own immune system fight cancer. The goal is to address the unmet need for long-term survival in patients with advanced cancers.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Oncology Immuno Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncology Immuno Drug.
The Oncology Immuno Drug market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Oncology Immuno Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oncology Immuno Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Oncology Immuno Drug Market Report

Report Metric Details
Report Name Oncology Immuno Drug Market
Accounted market size in year US$ 2541 million
Forecasted market size in 2031 US$ 4395 million
CAGR 8.3%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
  • Hospitals
  • Drugstores
  • Others
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Bristol-Myers Squibb, Merck & Co, Roche AG, AstraZeneca, Sanofi S.A., Dendreon Pharmaceuticals, Novartis, Gilead Sciences Inc., Merck KGaA
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Oncology Immuno Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Oncology Immuno Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Oncology Immuno Drug Market growing?

Ans: The Oncology Immuno Drug Market witnessing a CAGR of 8.3% during the forecast period 2025-2031.

What is the Oncology Immuno Drug Market size in 2031?

Ans: The Oncology Immuno Drug Market size in 2031 will be US$ 4395 million.

Who are the main players in the Oncology Immuno Drug Market report?

Ans: The main players in the Oncology Immuno Drug Market are Bristol-Myers Squibb, Merck & Co, Roche AG, AstraZeneca, Sanofi S.A., Dendreon Pharmaceuticals, Novartis, Gilead Sciences Inc., Merck KGaA

What are the Application segmentation covered in the Oncology Immuno Drug Market report?

Ans: The Applications covered in the Oncology Immuno Drug Market report are Hospitals, Drugstores, Others

What are the Type segmentation covered in the Oncology Immuno Drug Market report?

Ans: The Types covered in the Oncology Immuno Drug Market report are Immune Checkpoint Inhibitors, Cytokine-Based Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy, Other

Recommended Reports

Cancer Drug Therapies

Cancer Diagnostics

Lymphoma & Hematology

1 Oncology Immuno Drug Market Overview
1.1 Product Definition
1.2 Oncology Immuno Drug by Type
1.2.1 Global Oncology Immuno Drug Market Value Comparison by Type (2024 VS 2031)
1.2.2 Immune Checkpoint Inhibitors
1.2.3 Cytokine-Based Immunotherapy
1.2.4 Cancer Vaccines
1.2.5 CAR-T Cell Therapy
1.2.6 Other
1.3 Oncology Immuno Drug by Application
1.3.1 Global Oncology Immuno Drug Market Value by Application (2024 VS 2031)
1.3.2 Hospitals
1.3.3 Drugstores
1.3.4 Others
1.4 Global Oncology Immuno Drug Market Size Estimates and Forecasts
1.4.1 Global Oncology Immuno Drug Revenue 2020-2031
1.4.2 Global Oncology Immuno Drug Sales 2020-2031
1.4.3 Global Oncology Immuno Drug Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Oncology Immuno Drug Market Competition by Manufacturers
2.1 Global Oncology Immuno Drug Sales Market Share by Manufacturers (2020-2025)
2.2 Global Oncology Immuno Drug Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Oncology Immuno Drug Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Oncology Immuno Drug, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Oncology Immuno Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Oncology Immuno Drug, Product Type & Application
2.7 Global Key Manufacturers of Oncology Immuno Drug, Date of Enter into This Industry
2.8 Global Oncology Immuno Drug Market Competitive Situation and Trends
2.8.1 Global Oncology Immuno Drug Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Oncology Immuno Drug Players Market Share by Revenue
2.8.3 Global Oncology Immuno Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Oncology Immuno Drug Market Scenario by Region
3.1 Global Oncology Immuno Drug Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Oncology Immuno Drug Sales by Region: 2020-2031
3.2.1 Global Oncology Immuno Drug Sales by Region: 2020-2025
3.2.2 Global Oncology Immuno Drug Sales by Region: 2026-2031
3.3 Global Oncology Immuno Drug Revenue by Region: 2020-2031
3.3.1 Global Oncology Immuno Drug Revenue by Region: 2020-2025
3.3.2 Global Oncology Immuno Drug Revenue by Region: 2026-2031
3.4 North America Oncology Immuno Drug Market Facts & Figures by Country
3.4.1 North America Oncology Immuno Drug Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Oncology Immuno Drug Sales by Country (2020-2031)
3.4.3 North America Oncology Immuno Drug Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Oncology Immuno Drug Market Facts & Figures by Country
3.5.1 Europe Oncology Immuno Drug Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Oncology Immuno Drug Sales by Country (2020-2031)
3.5.3 Europe Oncology Immuno Drug Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Oncology Immuno Drug Market Facts & Figures by Region
3.6.1 Asia Pacific Oncology Immuno Drug Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Oncology Immuno Drug Sales by Region (2020-2031)
3.6.3 Asia Pacific Oncology Immuno Drug Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Oncology Immuno Drug Market Facts & Figures by Country
3.7.1 Latin America Oncology Immuno Drug Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Oncology Immuno Drug Sales by Country (2020-2031)
3.7.3 Latin America Oncology Immuno Drug Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Oncology Immuno Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Oncology Immuno Drug Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Oncology Immuno Drug Sales by Country (2020-2031)
3.8.3 Middle East and Africa Oncology Immuno Drug Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Oncology Immuno Drug Sales by Type (2020-2031)
4.1.1 Global Oncology Immuno Drug Sales by Type (2020-2025)
4.1.2 Global Oncology Immuno Drug Sales by Type (2026-2031)
4.1.3 Global Oncology Immuno Drug Sales Market Share by Type (2020-2031)
4.2 Global Oncology Immuno Drug Revenue by Type (2020-2031)
4.2.1 Global Oncology Immuno Drug Revenue by Type (2020-2025)
4.2.2 Global Oncology Immuno Drug Revenue by Type (2026-2031)
4.2.3 Global Oncology Immuno Drug Revenue Market Share by Type (2020-2031)
4.3 Global Oncology Immuno Drug Price by Type (2020-2031)
5 Segment by Application
5.1 Global Oncology Immuno Drug Sales by Application (2020-2031)
5.1.1 Global Oncology Immuno Drug Sales by Application (2020-2025)
5.1.2 Global Oncology Immuno Drug Sales by Application (2026-2031)
5.1.3 Global Oncology Immuno Drug Sales Market Share by Application (2020-2031)
5.2 Global Oncology Immuno Drug Revenue by Application (2020-2031)
5.2.1 Global Oncology Immuno Drug Revenue by Application (2020-2025)
5.2.2 Global Oncology Immuno Drug Revenue by Application (2026-2031)
5.2.3 Global Oncology Immuno Drug Revenue Market Share by Application (2020-2031)
5.3 Global Oncology Immuno Drug Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Bristol-Myers Squibb
6.1.1 Bristol-Myers Squibb Company Information
6.1.2 Bristol-Myers Squibb Description and Business Overview
6.1.3 Bristol-Myers Squibb Oncology Immuno Drug Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Bristol-Myers Squibb Oncology Immuno Drug Product Portfolio
6.1.5 Bristol-Myers Squibb Recent Developments/Updates
6.2 Merck & Co
6.2.1 Merck & Co Company Information
6.2.2 Merck & Co Description and Business Overview
6.2.3 Merck & Co Oncology Immuno Drug Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Merck & Co Oncology Immuno Drug Product Portfolio
6.2.5 Merck & Co Recent Developments/Updates
6.3 Roche AG
6.3.1 Roche AG Company Information
6.3.2 Roche AG Description and Business Overview
6.3.3 Roche AG Oncology Immuno Drug Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Roche AG Oncology Immuno Drug Product Portfolio
6.3.5 Roche AG Recent Developments/Updates
6.4 AstraZeneca
6.4.1 AstraZeneca Company Information
6.4.2 AstraZeneca Description and Business Overview
6.4.3 AstraZeneca Oncology Immuno Drug Sales, Revenue and Gross Margin (2020-2025)
6.4.4 AstraZeneca Oncology Immuno Drug Product Portfolio
6.4.5 AstraZeneca Recent Developments/Updates
6.5 Sanofi S.A.
6.5.1 Sanofi S.A. Company Information
6.5.2 Sanofi S.A. Description and Business Overview
6.5.3 Sanofi S.A. Oncology Immuno Drug Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Sanofi S.A. Oncology Immuno Drug Product Portfolio
6.5.5 Sanofi S.A. Recent Developments/Updates
6.6 Dendreon Pharmaceuticals
6.6.1 Dendreon Pharmaceuticals Company Information
6.6.2 Dendreon Pharmaceuticals Description and Business Overview
6.6.3 Dendreon Pharmaceuticals Oncology Immuno Drug Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Dendreon Pharmaceuticals Oncology Immuno Drug Product Portfolio
6.6.5 Dendreon Pharmaceuticals Recent Developments/Updates
6.7 Novartis
6.7.1 Novartis Company Information
6.7.2 Novartis Description and Business Overview
6.7.3 Novartis Oncology Immuno Drug Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Novartis Oncology Immuno Drug Product Portfolio
6.7.5 Novartis Recent Developments/Updates
6.8 Gilead Sciences Inc.
6.8.1 Gilead Sciences Inc. Company Information
6.8.2 Gilead Sciences Inc. Description and Business Overview
6.8.3 Gilead Sciences Inc. Oncology Immuno Drug Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Gilead Sciences Inc. Oncology Immuno Drug Product Portfolio
6.8.5 Gilead Sciences Inc. Recent Developments/Updates
6.9 Merck KGaA
6.9.1 Merck KGaA Company Information
6.9.2 Merck KGaA Description and Business Overview
6.9.3 Merck KGaA Oncology Immuno Drug Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Merck KGaA Oncology Immuno Drug Product Portfolio
6.9.5 Merck KGaA Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Oncology Immuno Drug Industry Chain Analysis
7.2 Oncology Immuno Drug Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Oncology Immuno Drug Production Mode & Process Analysis
7.4 Oncology Immuno Drug Sales and Marketing
7.4.1 Oncology Immuno Drug Sales Channels
7.4.2 Oncology Immuno Drug Distributors
7.5 Oncology Immuno Drug Customer Analysis
8 Oncology Immuno Drug Market Dynamics
8.1 Oncology Immuno Drug Industry Trends
8.2 Oncology Immuno Drug Market Drivers
8.3 Oncology Immuno Drug Market Challenges
8.4 Oncology Immuno Drug Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Bristol–Myers Squibb
Merck
Roche
Astrazeneca plc
Sanofi
Dendreon Pharmaceuticals
Novartis
Gilead Sciences Inc
Merck KGaA
List of Tables
 Table 1. Global Oncology Immuno Drug Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Oncology Immuno Drug Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Oncology Immuno Drug Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Oncology Immuno Drug Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Oncology Immuno Drug Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Oncology Immuno Drug Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Oncology Immuno Drug Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Oncology Immuno Drug Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Oncology Immuno Drug, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Oncology Immuno Drug, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Oncology Immuno Drug, Product Type & Application
 Table 12. Global Key Manufacturers of Oncology Immuno Drug, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Oncology Immuno Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Oncology Immuno Drug as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Oncology Immuno Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Oncology Immuno Drug Sales by Region (2020-2025) & (K Units)
 Table 18. Global Oncology Immuno Drug Sales Market Share by Region (2020-2025)
 Table 19. Global Oncology Immuno Drug Sales by Region (2026-2031) & (K Units)
 Table 20. Global Oncology Immuno Drug Sales Market Share by Region (2026-2031)
 Table 21. Global Oncology Immuno Drug Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Oncology Immuno Drug Revenue Market Share by Region (2020-2025)
 Table 23. Global Oncology Immuno Drug Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Oncology Immuno Drug Revenue Market Share by Region (2026-2031)
 Table 25. North America Oncology Immuno Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Oncology Immuno Drug Sales by Country (2020-2025) & (K Units)
 Table 27. North America Oncology Immuno Drug Sales by Country (2026-2031) & (K Units)
 Table 28. North America Oncology Immuno Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Oncology Immuno Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Oncology Immuno Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Oncology Immuno Drug Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Oncology Immuno Drug Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Oncology Immuno Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Oncology Immuno Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Oncology Immuno Drug Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Oncology Immuno Drug Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Oncology Immuno Drug Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Oncology Immuno Drug Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Oncology Immuno Drug Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Oncology Immuno Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Oncology Immuno Drug Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Oncology Immuno Drug Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Oncology Immuno Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Oncology Immuno Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Oncology Immuno Drug Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Oncology Immuno Drug Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Oncology Immuno Drug Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Oncology Immuno Drug Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Oncology Immuno Drug Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Oncology Immuno Drug Sales (K Units) by Type (2020-2025)
 Table 51. Global Oncology Immuno Drug Sales (K Units) by Type (2026-2031)
 Table 52. Global Oncology Immuno Drug Sales Market Share by Type (2020-2025)
 Table 53. Global Oncology Immuno Drug Sales Market Share by Type (2026-2031)
 Table 54. Global Oncology Immuno Drug Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Oncology Immuno Drug Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Oncology Immuno Drug Revenue Market Share by Type (2020-2025)
 Table 57. Global Oncology Immuno Drug Revenue Market Share by Type (2026-2031)
 Table 58. Global Oncology Immuno Drug Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Oncology Immuno Drug Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Oncology Immuno Drug Sales (K Units) by Application (2020-2025)
 Table 61. Global Oncology Immuno Drug Sales (K Units) by Application (2026-2031)
 Table 62. Global Oncology Immuno Drug Sales Market Share by Application (2020-2025)
 Table 63. Global Oncology Immuno Drug Sales Market Share by Application (2026-2031)
 Table 64. Global Oncology Immuno Drug Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Oncology Immuno Drug Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Oncology Immuno Drug Revenue Market Share by Application (2020-2025)
 Table 67. Global Oncology Immuno Drug Revenue Market Share by Application (2026-2031)
 Table 68. Global Oncology Immuno Drug Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Oncology Immuno Drug Price (US$/Unit) by Application (2026-2031)
 Table 70. Bristol-Myers Squibb Company Information
 Table 71. Bristol-Myers Squibb Description and Business Overview
 Table 72. Bristol-Myers Squibb Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. Bristol-Myers Squibb Oncology Immuno Drug Product
 Table 74. Bristol-Myers Squibb Recent Developments/Updates
 Table 75. Merck & Co Company Information
 Table 76. Merck & Co Description and Business Overview
 Table 77. Merck & Co Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Merck & Co Oncology Immuno Drug Product
 Table 79. Merck & Co Recent Developments/Updates
 Table 80. Roche AG Company Information
 Table 81. Roche AG Description and Business Overview
 Table 82. Roche AG Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Roche AG Oncology Immuno Drug Product
 Table 84. Roche AG Recent Developments/Updates
 Table 85. AstraZeneca Company Information
 Table 86. AstraZeneca Description and Business Overview
 Table 87. AstraZeneca Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. AstraZeneca Oncology Immuno Drug Product
 Table 89. AstraZeneca Recent Developments/Updates
 Table 90. Sanofi S.A. Company Information
 Table 91. Sanofi S.A. Description and Business Overview
 Table 92. Sanofi S.A. Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Sanofi S.A. Oncology Immuno Drug Product
 Table 94. Sanofi S.A. Recent Developments/Updates
 Table 95. Dendreon Pharmaceuticals Company Information
 Table 96. Dendreon Pharmaceuticals Description and Business Overview
 Table 97. Dendreon Pharmaceuticals Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Dendreon Pharmaceuticals Oncology Immuno Drug Product
 Table 99. Dendreon Pharmaceuticals Recent Developments/Updates
 Table 100. Novartis Company Information
 Table 101. Novartis Description and Business Overview
 Table 102. Novartis Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Novartis Oncology Immuno Drug Product
 Table 104. Novartis Recent Developments/Updates
 Table 105. Gilead Sciences Inc. Company Information
 Table 106. Gilead Sciences Inc. Description and Business Overview
 Table 107. Gilead Sciences Inc. Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Gilead Sciences Inc. Oncology Immuno Drug Product
 Table 109. Gilead Sciences Inc. Recent Developments/Updates
 Table 110. Merck KGaA Company Information
 Table 111. Merck KGaA Description and Business Overview
 Table 112. Merck KGaA Oncology Immuno Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Merck KGaA Oncology Immuno Drug Product
 Table 114. Merck KGaA Recent Developments/Updates
 Table 115. Key Raw Materials Lists
 Table 116. Raw Materials Key Suppliers Lists
 Table 117. Oncology Immuno Drug Distributors List
 Table 118. Oncology Immuno Drug Customers List
 Table 119. Oncology Immuno Drug Market Trends
 Table 120. Oncology Immuno Drug Market Drivers
 Table 121. Oncology Immuno Drug Market Challenges
 Table 122. Oncology Immuno Drug Market Restraints
 Table 123. Research Programs/Design for This Report
 Table 124. Key Data Information from Secondary Sources
 Table 125. Key Data Information from Primary Sources
 Table 126. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Oncology Immuno Drug
 Figure 2. Global Oncology Immuno Drug Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Oncology Immuno Drug Market Share by Type: 2024 & 2031
 Figure 4. Immune Checkpoint Inhibitors Product Picture
 Figure 5. Cytokine-Based Immunotherapy Product Picture
 Figure 6. Cancer Vaccines Product Picture
 Figure 7. CAR-T Cell Therapy Product Picture
 Figure 8. Other Product Picture
 Figure 9. Global Oncology Immuno Drug Market Value by Application (2020-2031) & (US$ Million)
 Figure 10. Global Oncology Immuno Drug Market Share by Application: 2024 & 2031
 Figure 11. Hospitals
 Figure 12. Drugstores
 Figure 13. Others
 Figure 14. Global Oncology Immuno Drug Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 15. Global Oncology Immuno Drug Market Size (2020-2031) & (US$ Million)
 Figure 16. Global Oncology Immuno Drug Sales (2020-2031) & (K Units)
 Figure 17. Global Oncology Immuno Drug Average Price (US$/Unit) & (2020-2031)
 Figure 18. Oncology Immuno Drug Report Years Considered
 Figure 19. Oncology Immuno Drug Sales Share by Manufacturers in 2024
 Figure 20. Global Oncology Immuno Drug Revenue Share by Manufacturers in 2024
 Figure 21. Global 5 and 10 Largest Oncology Immuno Drug Players: Market Share by Revenue in Oncology Immuno Drug in 2024
 Figure 22. Oncology Immuno Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 23. Global Oncology Immuno Drug Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 24. North America Oncology Immuno Drug Sales Market Share by Country (2020-2031)
 Figure 25. North America Oncology Immuno Drug Revenue Market Share by Country (2020-2031)
 Figure 26. United States Oncology Immuno Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. Canada Oncology Immuno Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. Europe Oncology Immuno Drug Sales Market Share by Country (2020-2031)
 Figure 29. Europe Oncology Immuno Drug Revenue Market Share by Country (2020-2031)
 Figure 30. Germany Oncology Immuno Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. France Oncology Immuno Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. U.K. Oncology Immuno Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Italy Oncology Immuno Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Russia Oncology Immuno Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Asia Pacific Oncology Immuno Drug Sales Market Share by Region (2020-2031)
 Figure 36. Asia Pacific Oncology Immuno Drug Revenue Market Share by Region (2020-2031)
 Figure 37. China Oncology Immuno Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Japan Oncology Immuno Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. South Korea Oncology Immuno Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. India Oncology Immuno Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Australia Oncology Immuno Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. China Taiwan Oncology Immuno Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Indonesia Oncology Immuno Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Thailand Oncology Immuno Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Malaysia Oncology Immuno Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Latin America Oncology Immuno Drug Sales Market Share by Country (2020-2031)
 Figure 47. Latin America Oncology Immuno Drug Revenue Market Share by Country (2020-2031)
 Figure 48. Mexico Oncology Immuno Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Brazil Oncology Immuno Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Argentina Oncology Immuno Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Middle East and Africa Oncology Immuno Drug Sales Market Share by Country (2020-2031)
 Figure 52. Middle East and Africa Oncology Immuno Drug Revenue Market Share by Country (2020-2031)
 Figure 53. Turkey Oncology Immuno Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. Saudi Arabia Oncology Immuno Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. UAE Oncology Immuno Drug Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 56. Global Sales Market Share of Oncology Immuno Drug by Type (2020-2031)
 Figure 57. Global Revenue Market Share of Oncology Immuno Drug by Type (2020-2031)
 Figure 58. Global Oncology Immuno Drug Price (US$/Unit) by Type (2020-2031)
 Figure 59. Global Sales Market Share of Oncology Immuno Drug by Application (2020-2031)
 Figure 60. Global Revenue Market Share of Oncology Immuno Drug by Application (2020-2031)
 Figure 61. Global Oncology Immuno Drug Price (US$/Unit) by Application (2020-2031)
 Figure 62. Oncology Immuno Drug Value Chain
 Figure 63. Channels of Distribution (Direct Vs Distribution)
 Figure 64. Bottom-up and Top-down Approaches for This Report
 Figure 65. Data Triangulation
 Figure 66. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Leap India

SIMILAR REPORTS

Immuno Oncology Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Oncology Immunotherapy Market
Global Immuno Oncology Service Market Research Report 2024
Global Immuno oncology Therapy Market Insights Forecast to 2030
Global Immuno oncology Clinical Trials Market Research Report 2024
Immuno oncology Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Immuno Oncology Assays Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Oncology Small Molecule Drugs Market Insights Forecast to 2030
Global Immuno Oncology Treatment Market Insights Forecast to 2030
Global Immuno Oncology Assays Kit Market Insights Forecast to 2030
Global Oncology Injection Drug Market Research Report 2025
Immuno oncology Diagnosis Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Immunotherapy Drugs Market Research Report 2024
Cancer Immunotherapy Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Oncology EMR Software Market Insights Forecast to 2030
Global Immunotherapeutic Drugs Market Insights Forecast to 2030
Global Cancer Immunotherapy Drugs Market Research Report 2024
Oncology Anti cancer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Artificial Intelligence AI in Oncology Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Cancer Immuno Personalized Medicine Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions